Ay to assemble interactomes relevant to vascular inflammation and thrombosis in order to characterize further the pathogenesis of relevant cardiovascular diseases, particularly myocardial infarction (MI). The National Institutes of Health-sponsored consortium MAPGen (www.mapgenprogram.org), for example, consists of five university centers with access to large human sample repositories and clinical data from international, multi-centered cardiovascular trials that are anticipated to generate broad and unbiased inflammasome and thrombosome networks. These large-scale individual networks and sub-networks created by overlap between them are currently being analyzed to define unrecognized protein-protein interactions pertinent to stroke, MI, and venous thromboemoblic disease. The selection of specific protein(s) or protein product(s) from this data set or other networks of similar scale for validation experimentally is likely to hinge on the strength of association, location of targets within the network, their proximity to other important protein/products, and/or data linking naturally-occurring loss- or gain-of-function mutations of the putative target to relevant clinical disorders, among other factors. While systematic analysis of data from the MAPGen project is forthcoming, other reports from smaller cardiovascular disease datasets have emerged. For example, proteomic analysis of circulating microvesicles harvested from patients with acute ST-segment elevation myocardial infarction or stable coronary artery disease was performed by mass spectrometry 67. Using this approach, investigators were able to identify 117 proteins that varied by at least 2-fold between groups, such as 2-macroglobulin isoforms and fibrinogen.Author Manuscript Author Manuscript Author Manuscript Author ManuscriptWiley Interdiscip Rev Syst Biol Med. Author manuscript; available in PMC 2016 July 01.Wang et al.PageProtein discovery was then subjected to Ingenuity?pathway analysis to generate a proteinprotein interaction network. Findings from this work suggest that a majority of microvesiclederived proteins are located within inflammatory and thrombosis networks, LixisenatideMedChemExpress Lixisenatide affirming the contemporary view that myocardial infarction is a consequence of these interrelated processes. Parenchymal lung disease Owing to the complex interplay between numerous cell types comprising the lungpulmonary vascular axis, a number of important pathophenotypes affecting these systems have evolved as attractive fields for systems biology investigations 68. Along these lines, chronic obstructive pulmonary disease (COPD), which comprises a heterogeneous range of parenchymal lung disorders, has been increasingly studied using network analyses to parse out differences and similarities among patients with respect to gene expression profiles and subpathophenotypes. Using the novel diVIsive Shuffling Approach (VIStA) designed to optimize identification of patient subgroups through gene expression differences, it was demonstrated that Procyanidin B1 solubility characterizing COPD subtypes according to many common clinical characteristics was inefficacious at grouping patients according to overlap in gene expression differences 69. Important exceptions to this observation were airflow obstruction and emphysema severity, which proved to be drivers of COPD patients’ gene expression clustering. Among the most noteworthy of the secondary characteristics (i.e., functional to inform the genetic signature of COPD) was walk distance, rai.Ay to assemble interactomes relevant to vascular inflammation and thrombosis in order to characterize further the pathogenesis of relevant cardiovascular diseases, particularly myocardial infarction (MI). The National Institutes of Health-sponsored consortium MAPGen (www.mapgenprogram.org), for example, consists of five university centers with access to large human sample repositories and clinical data from international, multi-centered cardiovascular trials that are anticipated to generate broad and unbiased inflammasome and thrombosome networks. These large-scale individual networks and sub-networks created by overlap between them are currently being analyzed to define unrecognized protein-protein interactions pertinent to stroke, MI, and venous thromboemoblic disease. The selection of specific protein(s) or protein product(s) from this data set or other networks of similar scale for validation experimentally is likely to hinge on the strength of association, location of targets within the network, their proximity to other important protein/products, and/or data linking naturally-occurring loss- or gain-of-function mutations of the putative target to relevant clinical disorders, among other factors. While systematic analysis of data from the MAPGen project is forthcoming, other reports from smaller cardiovascular disease datasets have emerged. For example, proteomic analysis of circulating microvesicles harvested from patients with acute ST-segment elevation myocardial infarction or stable coronary artery disease was performed by mass spectrometry 67. Using this approach, investigators were able to identify 117 proteins that varied by at least 2-fold between groups, such as 2-macroglobulin isoforms and fibrinogen.Author Manuscript Author Manuscript Author Manuscript Author ManuscriptWiley Interdiscip Rev Syst Biol Med. Author manuscript; available in PMC 2016 July 01.Wang et al.PageProtein discovery was then subjected to Ingenuity?pathway analysis to generate a proteinprotein interaction network. Findings from this work suggest that a majority of microvesiclederived proteins are located within inflammatory and thrombosis networks, affirming the contemporary view that myocardial infarction is a consequence of these interrelated processes. Parenchymal lung disease Owing to the complex interplay between numerous cell types comprising the lungpulmonary vascular axis, a number of important pathophenotypes affecting these systems have evolved as attractive fields for systems biology investigations 68. Along these lines, chronic obstructive pulmonary disease (COPD), which comprises a heterogeneous range of parenchymal lung disorders, has been increasingly studied using network analyses to parse out differences and similarities among patients with respect to gene expression profiles and subpathophenotypes. Using the novel diVIsive Shuffling Approach (VIStA) designed to optimize identification of patient subgroups through gene expression differences, it was demonstrated that characterizing COPD subtypes according to many common clinical characteristics was inefficacious at grouping patients according to overlap in gene expression differences 69. Important exceptions to this observation were airflow obstruction and emphysema severity, which proved to be drivers of COPD patients’ gene expression clustering. Among the most noteworthy of the secondary characteristics (i.e., functional to inform the genetic signature of COPD) was walk distance, rai.